Sanofi’s rimonabant from A to Z
The Endocrinologic and Metabolic Drugs Advisory Committee will convene June 13 to discuss efficacy and safety data for Sanofi-Aventis' potential first-in-class obesity agent rimonabant. The proposed trade name for the CB-1 receptor agonist, previously known as Acomplia in the U.S., is Zimulti. The committee will review rimonabant's use as an adjunct to diet and exercise for obesity management in patients. Sanofi announced in February that FDA extended rimonabant's user fee date by three months, which would set a late July user fee action date (1"The Pink Sheet" Feb. 19, 2007, p. 19). The meeting will take place at the Hilton in Silver Spring, Md., from 8 a.m. to 5 p.m...
You may also be interested in...
Sanofi-Aventis is positioning Acomplia as part of a comprehensive cardio-metabolic disease management program that includes patient and physician support services
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.